Introduction
Cellectis (CLLS) is a clinical-stage biotechnology company developing off-the-shelf, allogeneic CAR T (“UCART”) therapies with its leadership in gene editing through its flagship technology, TALEN, which has been successfully used in the clinic to solve key challenges associated with allogeneic CAR-Ts such as Graft vs. Host Disease.
Cellectis is advancing UCART product candidates in various indications including acute myeloid leukemia (“AML”), B-cell acute lymphoblastic leukemia (“B-ALL”), multiple myeloma (“MM), Hodgkin lymphoma (“HL”) and non-Hodgkin lymphoma (“NHL”).
Its key partners include Allogene Therapeutics (“ALLO”) and Servier, both of which have licensed product candidates